临床与病理杂志
臨床與病理雜誌
림상여병리잡지
International Journal of Pathology and Clinical Medicine
2015年
8期
1533-1536
,共4页
类风湿关节炎%环孢素A%甲氨蝶呤%IL-17
類風濕關節炎%環孢素A%甲氨蝶呤%IL-17
류풍습관절염%배포소A%갑안접령%IL-17
rheumatoid arthritis%cyclosporin A%methotrexate%IL-17
目的：研究环孢素A(ciclosporin A，CsA)联合甲氨蝶呤(methotrexate，MTX)治疗对类风湿关节炎(rheumatoid arthritis，RA)患者血清IL-17的表达影响，揭示CsA联合MTX治疗RA的作用机制。方法：收集83例RA经MTX单药或联合CsA治疗的新确诊患者，以及健康志愿者31例。MTX单药治疗组(41例)每周予以MTX(10~15 mg)；CsA联合MTX治疗组42例，予以CsA 3 mg/kg/d和MTX(10~15 mg)每周1次；观察和评价患者治疗3月后血清中IL-17的表达变化，以及与疾病活动度评分、RF、anti-CCP之间的关系。结果：两组RA患者治疗前血清IL-17表达均显著高于正常健康对照组(P<0.001)。与治疗前相比，两组血清中IL-17表达均下降，但MTX单药治疗组无差异性(P=0.062)，联合治疗组中IL-17表达显著性下降(P=0.016)。在MTX和CsA联合治疗组中，IL-17的变化值与anti-CCP(r=0.42，P=0.041)和DAS28(r=0.49，P=0.023)的变化值具有相关性。结论：CsA联合MTX治疗RA的机制与抑制IL-17的表达有一定关系。
目的：研究環孢素A(ciclosporin A，CsA)聯閤甲氨蝶呤(methotrexate，MTX)治療對類風濕關節炎(rheumatoid arthritis，RA)患者血清IL-17的錶達影響，揭示CsA聯閤MTX治療RA的作用機製。方法：收集83例RA經MTX單藥或聯閤CsA治療的新確診患者，以及健康誌願者31例。MTX單藥治療組(41例)每週予以MTX(10~15 mg)；CsA聯閤MTX治療組42例，予以CsA 3 mg/kg/d和MTX(10~15 mg)每週1次；觀察和評價患者治療3月後血清中IL-17的錶達變化，以及與疾病活動度評分、RF、anti-CCP之間的關繫。結果：兩組RA患者治療前血清IL-17錶達均顯著高于正常健康對照組(P<0.001)。與治療前相比，兩組血清中IL-17錶達均下降，但MTX單藥治療組無差異性(P=0.062)，聯閤治療組中IL-17錶達顯著性下降(P=0.016)。在MTX和CsA聯閤治療組中，IL-17的變化值與anti-CCP(r=0.42，P=0.041)和DAS28(r=0.49，P=0.023)的變化值具有相關性。結論：CsA聯閤MTX治療RA的機製與抑製IL-17的錶達有一定關繫。
목적：연구배포소A(ciclosporin A，CsA)연합갑안접령(methotrexate，MTX)치료대류풍습관절염(rheumatoid arthritis，RA)환자혈청IL-17적표체영향，게시CsA연합MTX치료RA적작용궤제。방법：수집83례RA경MTX단약혹연합CsA치료적신학진환자，이급건강지원자31례。MTX단약치료조(41례)매주여이MTX(10~15 mg)；CsA연합MTX치료조42례，여이CsA 3 mg/kg/d화MTX(10~15 mg)매주1차；관찰화평개환자치료3월후혈청중IL-17적표체변화，이급여질병활동도평분、RF、anti-CCP지간적관계。결과：량조RA환자치료전혈청IL-17표체균현저고우정상건강대조조(P<0.001)。여치료전상비，량조혈청중IL-17표체균하강，단MTX단약치료조무차이성(P=0.062)，연합치료조중IL-17표체현저성하강(P=0.016)。재MTX화CsA연합치료조중，IL-17적변화치여anti-CCP(r=0.42，P=0.041)화DAS28(r=0.49，P=0.023)적변화치구유상관성。결론：CsA연합MTX치료RA적궤제여억제IL-17적표체유일정관계。
Objective: To investigate the role of cyclosporin A (CsA) and methotrexate (MTX) combined therapy in modulation of serum IL-17 express in the patients with rheumatoid arthritis (RA).Methods: 83 new patients with rheumatoid arthritis were collected, which consist of MTX monotherapy (41 cases) and combination of MTX and CsA therapy (42 cases). hTe MTX dose was applied for 10~15 mg per week, and CsA was 3 mg/kg per day. hTe sera IL-17 expression was detected by ELISA before therapy and atfer 3 months treatment. In addition, disease activity index, RF and anti-CCP were also evaluated, and corelation between IL-17 and above clinical parameters were analyzed.Results:hTe levels of IL-17 in AR patients and healthy volunteers were analyzed. As compared with healthy control, AR patients have high level of IL-17 (P<0.001), two group AR patients has no difference. Interestingly, when compared with pre-treatment, the expression of IL-17 was signiifcantly decreased in AR patients with MTX and CsA treatment (P=0.016), while MTX monotherapy has no considerable change (P=0.062). In the MTX and CsA treated group, correlations between the difference of IL-17 and those of clinical <br> and laboratory parameters at baseline and 3 months from initial treatment showed significant correlation with anti-CCP (r=0.42,P=0.041) and DAS28 (r=0.49,P=0.023).Conclusion:The mechanism of CsA and MTX combined therapy in the patients with rheumatoid arthritis might due to the inhibition of IL-17 expression.
